Send to a Friend Font Size: Increase Decrease

Viking Global Investors

Viking Global Investors 's Portfolio

Last Updated on 5/16/11 @ 05:55pm

Ticker	# of Shares	Price	Value
	143,085,126	$195.32	$27,947,386,811
	120,000,000	$195.32	$23,438,400,000
	75,238,700	$195.32	$14,695,622,884
MU	4,424,339	$971.32	$4,297,448,958
STX	3,186,400	$911.63	$2,904,817,832
GE	7,138,176	$329.65	$2,353,099,719
V	7,140,286	$322.66	$2,303,884,681
	9,798,229	$195.32	$1,913,790,089
PM	9,055,492	$183.45	$1,661,230,008
	6,639,199	$195.32	$1,296,768,349
View Additional Portfolio Information »

Viking Global Investors is a long/short equity hedge fund. The fund employs a bottom-up fundamental stock-picking strategy for its investments in equities in the U.S. and Europe. It focuses on the financial, telecommunication, media, technology, and consumer sectors. Viking Global Investors is based in New York and was founded in October, 1999 by Andreas Halvorsen, David Ott, and Brian Olson.

Messers. Halvorsen, Ott, and Olson worked together at Tiger Management Corp. All three left Tiger in early 1999.

Login to help us fill in information about this entity.

Form SCHEDULE 13G/A STANDARD BIOTOOLS INC. Filed by: VIKING GLOBAL INVESTORS LP May 15, 2026 05:51PM

KeyBanc Reiterates Sector Weight Rating on Standard BioTools Inc (LAB) Aug 12, 2025 10:15AM

Form SC 13G/A STANDARD BIOTOOLS INC. Filed by: VIKING GLOBAL INVESTORS LP Mar 20, 2024 06:05PM

Form 3 STANDARD BIOTOOLS INC. For: Mar 18 Filed by: Viking Global Opportunities Illiquid Investments Sub-Master LP Mar 20, 2024 06:05PM

Standard BioTools (LAB) exchanged all outstanding shares of its Series B Convertible Preferred Stock for shares of common stock Mar 18, 2024 08:14AM

Mar 18, 2024 08:12AM Standard BioTools Announces Exchange of All Outstanding Series B Convertible Preferred Stock for Common Stock
Jan 9, 2024 04:47PM Form SC 13G STANDARD BIOTOOLS INC. Filed by: VIKING GLOBAL INVESTORS LP
Dec 12, 2023 05:31PM Madryn Asset Management, a Top Shareholder of SomaLogic, Issues Letter Regarding Opposition to the Company’s Proposed Merger with Standard BioTools
Nov 22, 2023 04:16PM Form SC 13D/A STANDARD BIOTOOLS INC. Filed by: VIKING GLOBAL INVESTORS LP
Oct 16, 2023 04:30PM Form SC 13D STANDARD BIOTOOLS INC. Filed by: VIKING GLOBAL INVESTORS LP
Feb 14, 2023 01:18PM Form SC 13G/A STANDARD BIOTOOLS INC. Filed by: VIKING GLOBAL INVESTORS LP
Aug 8, 2022 04:02PM Standard BioTools Announces Second Quarter 2022 Financial Results and Provides Strategic Update
May 5, 2022 04:02PM Standard BioTools Announces First Quarter 2022 Financial Results
Apr 14, 2022 05:10PM Form SC 13G STANDARD BIOTOOLS INC. Filed by: VIKING GLOBAL INVESTORS LP
Apr 4, 2022 05:32PM Fluidigm (FLDM) Completes $250 Million Strategic Capital Infusion and Changes Name to Standard BioTools Inc.
Apr 4, 2022 05:30PM Fluidigm Completes $250 Million Strategic Capital Infusion and Changes Name to Standard BioTools Inc.

Nasdaq		15000.33
	+57.68	(+0.39%)

S&P 500		4486.55
	+7.02	(+0.16%)

Market Snapshot

Free News Feed